MediWound's NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress
MWN-AI** Summary
MediWound Ltd. (Nasdaq: MDWD) is set to showcase its innovative enzymatic burn debridement therapy, NexoBrid®, in 36 scientific presentations at the 21st European Burns Association (EBA) Congress, occurring from September 3-6, 2025, in Berlin. This prominent participation underscores NexoBrid's significant contributions to burn care, with presentations emphasizing its efficacy in diverse patient demographics, including pediatric, elderly, and critically burned individuals.
Data presented at the congress will demonstrate NexoBrid's consistent benefits in survival rates, recovery trajectories, scar outcomes, and its role in infection control and managing systemic inflammatory responses. Comparative studies further highlight NexoBrid's advantages over traditional surgical excision, reinforcing its place in routine care and during mass casualty situations.
Alicia Torrenova, MediWound’s Vice President of European Operations, expressed optimism about the attention NexoBrid will receive at the EBA Congress, emphasizing the extensive clinical data and growing experience that support its use in advancing burn treatment. This reinforces the importance of ongoing research and collaboration among burn care professionals.
The EBA, established in 1981, aims to enhance standards of burn treatment, research, and prevention by promoting interdisciplinary collaboration within the burn care community. The biennial congress serves as a critical platform for sharing knowledge and best practices to improve patient outcomes.
NexoBrid is a biologically-derived orphan drug that selectively removes non-viable tissue in deep partial- and full-thickness thermal burns while preserving healthy tissue, and is approved in over 40 countries worldwide. MediWound continues to innovate in tissue repair treatments, focusing on their promising investigational therapy, EscharEx®, for chronic wound debridement, positioning itself as a leader in this vital medical field.
MWN-AI** Analysis
MediWound Ltd. (Nasdaq: MDWD) is positioning itself favorably within the burn treatment market, particularly with its innovative product, NexoBrid®. With NexoBrid being prominently featured in 36 scientific presentations at the upcoming 21st European Burns Association (EBA) Congress, investor sentiment is likely to improve as the product gains credibility among leading burn care specialists.
Notably, the congress will showcase success stories that underline NexoBrid's effectiveness in treating diverse patient groups, including pediatrics and critically burned individuals. The emphasis on comparative studies supporting its advantages over traditional surgical methods signifies not just acceptance in clinical circles but also the potential for increased market penetration. Given that NexoBrid has garnered regulatory approvals in over 40 countries, including major markets like the U.S. and Japan, the potential for revenue generation appears robust.
Moreover, MediWound's commitment to innovation, supported by funding from federal sources, is pivotal. This financial backing enables their further research initiatives and enhances the credibility of the product pipeline, including EscharEx®, which also targets significant market needs for chronic wounds.
For investors, the current momentum around NexoBrid suggests potential upside, particularly if the positive outcomes presented at the congress lead to increased adoption by healthcare professionals. However, while the growth prospects appear promising, risks exist, such as competition from other debridement therapies and shifts in regulatory landscapes.
In conclusion, MediWound’s stock represents a compelling opportunity in the biotech space, especially as NexoBrid gains further validation. Investors should monitor outcomes from the EBA congress closely, as favorable results could catalyze price appreciation. As long as the company continues to capitalize on its competitive strengths and navigate potential challenges effectively, MDWD shares could offer significant value moving forward.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
MediWound’s NexoBrid ® to be Highlighted in 36 Scientific Presentations at the 21 st European Burns Association Congress
YAVNE, Israel, September 2, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced its participation at the 21st European Burns Association (EBA) Congress, taking place September 3-6, 2025, in Berlin, Germany. NexoBrid ® , the company’s enzymatic burn debridement therapy, will be featured in 36 scientific oral and poster presentations delivered by leading burn specialists from across Europe, highlighting its role in advancing burn care.
The presentations include data on pediatric, elderly, and critically burned patients demonstrating consistent benefits in survival, recovery, and scar outcomes, as well as value in infection control and modulation of systemic inflammatory responses. Comparative and long-term studies further support NexoBrid’s superiority over surgical excision, reaffirming its role in both routine care and mass casualty scenarios.
“NexoBrid will be prominently highlighted throughout this year’s EBA Congress, reflecting the extensive clinical data and growing real-world experience across Europe,” said Alicia Torrenova, Vice President of European Operations at MediWound. “We are encouraged to see leading burn specialists share their findings, further establishing NexoBrid as an important therapy in advancing burn care.”
About the European Burns Association
The European Burns Association (EBA), founded in 1981, brings together burn care professionals from across Europe to advance standards of treatment, research, and prevention. As a multidisciplinary forum, the EBA promotes collaboration among physicians, researchers, allied health professionals, and organizations dedicated to improving outcomes for burn patients. Through its biennial congress and ongoing initiatives, the EBA fosters the exchange of knowledge and best practices to benefit the global burn care community.
About NexoBrid ®
NexoBrid ® is a topically administered, biological orphan drug for the enzymatic removal of eschar in patients with deep partial- and full-thickness thermal burns. It selectively removes non-viable tissue while preserving viable tissue and is approved for use in adults and pediatric patients in over 40 countries, including the United States, European Union, and Japan.
NexoBrid development has been supported in whole or in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract HHSO100201500035C. This contract provided funding and technical support for the pivotal U.S. Phase 3 clinical study (DETECT), the randomized, controlled pivotal clinical trial for use in the pediatric population (CIDS), the marketing approval registration process for NexoBrid as well as its procurement and availability under the expanded access treatment protocol (NEXT). Additional projects for evaluation of NexoBrid funded under the BARDA contract include establishment of a pre-emergency use data package and development of the health economic model to evaluate the cost savings impact to enable market adoption in the United States.
About MediWound
MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company focused on developing and commercializing enzymatic therapies for non-surgical tissue repair. The company’s FDA-approved biologic, NexoBrid ® , is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the U.S., European Union, Japan, and other international markets. MediWound is also advancing EscharEx ® , a late-stage investigational therapy for the debridement of chronic wounds. EscharEx has demonstrated clinical advantages over the leading enzymatic debridement product and targets a substantial global market opportunity.
For more information visit www.mediwound.com and follow us on LinkedIn .
MediWound Contacts: Media Contact:
Hani Luxenburg Daniel Ferry Ellie Hanson
Chief Financial Officer Managing Director Partner
MediWound Ltd. LifeSci Advisors, LLC FINN Partners for MediWound
ir@mediwound.com daniel@lifesciadvisors.com ellie.hanson@finnpartners.com
FAQ**
How does NexoBrid's efficacy in managing pediatric burn patients compare to traditional debridement methods, and what clinical data does MediWound Ltd. (Nasdaq: MDWD) present to support this?
What specific mechanisms of action allow NexoBrid to preserve viable tissue while effectively removing non-viable tissue, as highlighted by MediWound Ltd. (Nasdaq: MDWD) in the upcoming EBA Congress?
Can you elaborate on the long-term outcomes associated with NexoBrid use in critically burned patients and how these outcomes reinforce its role according to MediWound Ltd. (Nasdaq: MDWD)?
In terms of infection control and modulation of systemic inflammatory responses, what key findings will the 36 presentations at the EBA Congress reveal about NexoBrid, as emphasized by MediWound Ltd. (Nasdaq: MDWD)?
**MWN-AI FAQ is based on asking OpenAI questions about MediWound Ltd. (NASDAQ: MDWD).
NASDAQ: MDWD
MDWD Trading
-0.92% G/L:
$17.30 Last:
15,498 Volume:
$17.38 Open:
